发明专利
JP2006508984A Methods and compositions for the treatment of persistent neonatal pulmonary hypertension using the aralkyl ester soft drug
审中-公开
基本信息:
- 专利标题： Methods and compositions for the treatment of persistent neonatal pulmonary hypertension using the aralkyl ester soft drug
- 申请号：JP2004553810 申请日：2003-11-17
- 公开(公告)号：JP2006508984A 公开(公告)日：2006-03-16
- 发明人： アオウスマニー，モウスタファ・エム , エアハート，ポール・ダブリュー
- 申请人： ザ・ユニバーシティ・オブ・トレド
- 专利权人： ザ・ユニバーシティ・オブ・トレド
- 当前专利权人： ザ・ユニバーシティ・オブ・トレド
- 优先权： US29904402 2002-11-18
- 主分类号： A61K45/00
- IPC分类号： A61K45/00 ; C07D499/68 ; A61K31/185 ; A61K31/195 ; A61K31/216 ; A61K31/235 ; A61K31/24 ; A61K31/245 ; A61K31/277 ; A61K31/401 ; A61K31/4025 ; A61K31/405 ; A61K31/4164 ; A61K31/4166 ; A61K31/4168 ; A61K31/421 ; A61K31/426 ; A61K31/43 ; A61K31/4422 ; A61K31/454 ; A61K31/46 ; A61K31/517 ; A61K31/519 ; A61K31/522 ; A61K31/55 ; A61K31/58 ; A61K31/65 ; A61K31/66 ; A61K47/46 ; A61K47/48 ; A61P9/06 ; A61P9/12 ; A61P17/02 ; A61P17/06 ; A61P25/02 ; A61P29/00 ; A61P31/10 ; A61P35/00 ; A61P43/00 ; C07C217/40 ; C07C219/10 ; C07C219/14 ; C07C229/60 ; C07C237/04 ; C07D207/16 ; C07D209/26 ; C07D209/28 ; C07D211/90 ; C07D223/22 ; C07D233/06 ; C07D233/26 ; C07D233/50 ; C07D233/76 ; C07D261/16 ; C07D277/20 ; C07D277/56 ; C07D295/14 ; C07D401/06 ; C07D405/12 ; C07D451/06 ; C07D451/10 ; C07D473/06 ; C07D475/08 ; C07D501/22 ; C07J43/00
While changing one or more of the desired path and the speed by incorporating a predetermined chemical in a valid parent drug compounds in the metabolism of inert or very weak activity of the parent drug compounds directed to the non-toxic metabolites also expand the intravenous infusion of the modified drug to be formed so as to maintain the efficacy, methods and compositions for treating persistent pulmonary hypertension in human neonates is disclosed. Chemical arrangement, the φ-R-X-R '(φ, has been specially added to the parent drug compound through or a metabolically stable connections are already present in the parent drug compound phenyl , substituted aryl or heteroaryl system; R is 0 to an alkyl or alkene having a branched or unbranched carbon, metabolically to or φ already present in the parent drug compound are those attached to the parent drug compounds through a stable connection; X is carboxyl, which is metabolically specially added to the parent drug compounds through a stable connection to the R, in sulfoxyl or phosphatyl functional group There; and R 'is branched or unbranched alkyl having 1 to 10 carbons, or alkenyl or aralkyl group, or a structural element already present as the original part of the parent drug compound) it is.
信息查询:
EspacenetIPC结构图谱:
| A | 人类生活必需 |
| --A61 | 医学或兽医学；卫生学 |
| ----A61K | 医用、牙科用或梳妆用的配制品 |
| ------A61K45/00 | 在A61K31/00至A61K41/00各组中不包含的含有效成分的医用配制品 |